10-QPeriod: Q2 FY2007

GILEAD SCIENCES, INC. Quarterly Report for Q2 Ended Jun 30, 2007

Filed August 9, 2007For Securities:GILD

Summary

Gilead Sciences, Inc. reported strong revenue growth in the second quarter of 2007, with total revenues reaching $1.05 billion, a 53% increase year-over-year. This growth was primarily driven by a significant surge in HIV product sales, up 60% to $762.2 million, fueled by strong performance from Truvada and the successful launch of Atripla. Royalty revenue also saw a substantial increase of 59% to $135.7 million, largely due to higher Tamiflu royalties from Roche. While the company's financial performance is robust, investors should note the growing importance of the HIV franchise, which now accounts for a substantial majority of total revenues. The company's gross margin has seen a slight decrease due to a higher product mix from Atripla. Gilead continues to invest heavily in research and development, with R&D expenses increasing by 50% year-over-year, signaling a commitment to pipeline expansion. The company also completed its $1.0 billion stock repurchase program and implemented a two-for-one stock split.

Key Highlights

  • 1Total revenues surged 53% year-over-year to $1.05 billion in Q2 2007.
  • 2HIV product sales increased 60% to $762.2 million, driven by Truvada and Atripla.
  • 3Royalty revenue grew 59% to $135.7 million, boosted by Tamiflu royalties.
  • 4Gross margin slightly decreased to 80% due to product mix, particularly Atripla.
  • 5Research and Development expenses increased by 50% to $135.9 million.
  • 6The company completed its $1.0 billion stock repurchase program.
  • 7A two-for-one stock split was executed in June 2007.

Frequently Asked Questions

The primary drivers of Gilead's revenue growth were strong sales of its HIV products, particularly Truvada and the newly launched Atripla. Additionally, a significant increase in royalty revenue from Tamiflu sales by Roche contributed to the overall revenue increase.

Gilead's product gross margin decreased to 80% in Q2 2007 from 87% in the prior year. This was primarily attributed to a shift in product mix, with Atripla, which has a lower gross margin due to the inclusion of the Sustiva component from a joint venture, representing a larger portion of total sales.

Gilead is actively investing in its pipeline, with R&D expenses increasing by 50% year-over-year. Key developments include progress in Phase 3 trials for Viread for chronic hepatitis B and for darusentan for resistant hypertension, as well as positive results for aztreonam lysine for inhalation for cystic fibrosis. The company also launched Letairis for pulmonary arterial hypertension in June 2007.

Gilead announced the completion of its $1.0 billion stock repurchase program in Q2 2007. The company also executed a two-for-one stock split in June 2007. Its cash, cash equivalents, and marketable securities increased significantly, providing resources for corporate development and operational needs.